Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 399)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Carmustine |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
154-93-8 |
2578
|
Synonyms:
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
Becenum
Becenun
Bi CNU
BiCNU
Bicnu (tn)
BiCNU (TN)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
bis-chloroethylnitrosourea
Bischloroethylnitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
BRN 2049744
C 0400
C0400_SIGMA
C5H11Cl2N3O2
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
carmustine
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
carmustine in ethanol
Carmustinum
Carmustinum [INN-Latin]
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
D002330
D00254
DB00262
DivK1c_000835
DTI 015
|
EINECS 205-838-2
EU-0100188
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
Lopac0_000188
Lopac-C-0400
LS-890
MLS001333962
MolPort-003-665-505
N,N'-Bis(2-chloroethyl)-N-nitrosourea
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI60_003931
NCI-C04773
NINDS_000835
Nitrumon
NSC 409962
NSC409962
NSC-409962
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
Spectrum_000265
Spectrum4_000888
Spectrum5_000920
SRI 1720
STK624770
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
|
|
2 |
|
Lomustine |
Approved, Investigational |
Phase 3,Phase 1 |
|
13010-47-4 |
3950
|
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
BRN 2125058
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
CHEMBL514
Chloroethylcyclohexylnitrosourea
CID3950
CINU
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
HMS2090A17
|
HSDB 6519
I06-0087
ICIG 1109
Lomustina
Lomustina [INN-Spanish]
lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
LS-728
medac Brand of Lomustine
MolPort-001-768-818
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI60_041743
NCI-C04740
NCIMech_000220
NPFAPI-06
NSC 79037
NSC79037
NSC-79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
|
|
3 |
|
Procarbazine |
Approved, Investigational |
Phase 3,Phase 1,Phase 2 |
|
671-16-9 |
4915
|
Synonyms:
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC1L1J8E
AC-4547
Ambap671-16-9
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
C07402
C12H19N3O
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
I01-8931
Ibenzmethyzin
Ibenzmethyzine
IBZ
LS-7671
MBH
MIH
MolPort-005-940-370
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
|
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
Natulan
Natulanar
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-α-(2-methylhydrazino)-p-toluamide
NSC-77213
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
procarbazine
Procarbazine (INN)
Procarbazine [INN:BAN]
Procarbazine Monohydrochloride
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
SPBio_003112
SRI-10847
UNII-35S93Y190K
|
|
4 |
|
Trioxsalen |
Approved |
Phase 3,Phase 1 |
|
3902-71-4 |
5585
|
Synonyms:
2',4,8-Trimethylpsoralen
4,5',8-Trimethylpsoralen
4,8,5'-Trimethylpsoralen
6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
trimethylpsoralen
Trimethylpsoralen
Trioxisaleno
|
Trioxsalen
trioxysalen
Trioxysalen
Trioxysalene
Trioxysalenum
trisoralen
Trisoralen
|
|
5 |
|
Dacarbazine |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
4342-03-4 |
5351166
|
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(dimethyltriazeno)imidazole-5-carboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
Biocarbazin
Biocarbazine
Biocarbazine R
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
C6H10N6O
Carboxamide, Dimethyl Imidazole
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
D00288
D003606
D2390_SIGMA
D3634
Dacarbazin
Dacarbazina
dacarbazine
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
Dacatic
DB00851
Decarbazine
Deticene
DIC
|
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Di-me-triazenoimidazolecarboxamide
DivK1c_000326
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
Dtic-Dome
DTICDome
DTIC-Dome
Dtic-Dome (TN)
DTIE
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole carboxamide
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI60_004053
NCI-C04717
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC45388
NSC-45388
Prestwick_904
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
Spectrum_000884
SPECTRUM1500218
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
ST51014976
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
|
|
6 |
|
Temozolomide |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
85622-93-1 |
5394
|
Synonyms:
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide
3,4-dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide
3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
85622-93-1
8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one
AC1L1K9B
AC-758
BIDD:GT0204
Bio-0147
BRN 5547136
C047246
C6H6N6O2
CCRG 81045
CCRG-81045
CCRIS 8996
CHEBI:153686
CHEMBL810
CID5394
CPD000466338
D06067
DB00853
Essex brand of temozolomide
HMS2051O12
HMS2090B08
I06-0149
I14-1943
LS-80558
M B 39831
M & B 39831
M&B 39831
M&B-39831
|
M-39831
MB 39831
Methazolastone
MLS000759447
MLS001424028
MLS002701861
NCGC00167429-01
NCGC00167429-02
NCI60_003316
NSC 362856
NSC362856
NSC-362856
SAM001246636
Sch 52365
Sch-52365
Schering brand of temozolomide
Schering-Plough brand of temozolomide
SMR000466338
STK623541
Temodal
Temodal (TN)
Temodar
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
temozolomide
Témozolomide
Temozolomide (JAN/USAN/INN)
Temozolomide [INN:BAN]
Temozolomidum
Temozolomidum [Latin]
TL8005593
TMZ-Bioshuttle
UNII-YF1K15M17Y
ZINC01482184
|
|
7 |
|
Bevacizumab |
Approved, Investigational |
Phase 3,Phase 2,Phase 1 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
8 |
|
Carboplatin |
Approved |
Phase 3,Phase 2,Phase 1 |
|
41575-94-4 |
10339178
38904
498142
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
9 |
|
Leflunomide |
Approved, Investigational |
Phase 3 |
|
75706-12-6 |
3899
|
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
A77 1486
AB00052389
AC1L1GYK
AC1Q2EVA
AC-6796
AKOS000265193
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis Behring Brand of Leflunomide
Aventis Brand of Leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
Hoechst Brand of Leflunomide
HSDB 7289
HWA 486
HWA-486
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
KBioSS_000802
L 5025
|
L5025_SIGMA
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
leflunomide
Leflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
lefunamide
Lefunomide
Lefunomide [Inn-Spanish]
Lefunomide [INN-Spanish]
Lopac0_000649
Lopac-L-5025
LS-86580
MLS000069648
MLS-0003109.0001
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick_87
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
Spectrum_000322
SPECTRUM1503927
Spectrum5_000850
SU 101
SU 101 (pharmaceutical)
SU101
SU-101
TL8005179
UNII-G162GK9U4W
ZINC00004840
|
|
10 |
|
Vincristine |
Approved, Investigational |
Phase 3,Phase 1,Phase 2 |
|
2068-78-2, 57-22-7 |
5978
|
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
|
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
|
|
11 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
|
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
|
|
12 |
|
Methylphenidate |
Approved, Investigational |
Phase 3 |
|
20748-11-2, 113-45-1 |
4158
|
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
298-59-9 (hydrochloride)
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
4311/B Ciba
AC1L1HJM
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
C 4311
C07196
Calocain
Centedein
Centedrin
Centedrine
Centredin
CHEBI:6887
CHEMBL796
CID4158
Concerta
D04999
Daytrana
Daytrana (TN)
DB00422
DB06701
DEA No. 1724
d-methylphenidate HCl
D-Methylphenidate HCl
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
Meridil
Metadate
Metadate CD
Metadate ER
Methyl (2-phenyl-2-(2-piperidyl)acetate)
methyl 2-phenyl-2-piperidin-2-ylacetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
|
Methyl phenidylacetate
methyl phenyl(piperidin-2-yl)acetate
methyl α-phenyl-α-(2-piperidyl)acetate
methyl α-phenyl-α-2-piperidinylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
methylphenidate
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
Methylphenidate (USAN/INN)
Methylphenidate [INN:BAN]
Methylphenidate HCl
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
MethyPatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
MPH
nchembio.2007.55-comp28
NCI-C56280
Phenidylate
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin hydrochloride
Ritalin LA
Ritalin SR
Ritaline
Ritalin-SR
Ritcher works
Ritcher Works
Tsentedrin
UNII-207ZZ9QZ49
α-phenyl-2-piperidineacetic acid methyl ester
|
|
13 |
|
Morphine |
Approved, Investigational |
Phase 3 |
|
57-27-2 |
5288826
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
HSDB 2134
Infumorph
|
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
|
|
14 |
|
Donepezil |
Approved |
Phase 3,Phase 2 |
|
120014-06-4 |
3152
|
Synonyms:
( inverted exclamation markA)-E 2020
120014-06-4
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC1L1FAE
AC-6969
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
Donepezil
|
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum_001664
Spectrum5_001662
TL8000531
UNII-8SSC91326P
|
|
15 |
|
Isotretinoin |
Approved |
Phase 3,Phase 2,Phase 1 |
|
4759-48-2 |
5282379
5538
|
Synonyms:
(13-cis)-Retinoate
(13cis)-retinoic acid
(13-cis)-Retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7e,9e,11e,13Z)-Retinoic acid
(7E,9E,11E,13Z)-retinoic acid
13 cis retinoic acid
13 Cis-Retinoic Acid
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin a acid
13-cis-Vitamin A acid
13-RA
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
cis-RA
cis-Retinoate
cis-Retinoic acid
Claravis
CPD000471891
D00348
D015474
EINECS 225-296-0
EU-0101081
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
|
Isotretinoin (USP)
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoin Retinoic acid
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
isotretinoino
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
Lopac0_001081
LS-143465
MLS001074662
MolPort-003-666-394
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin a acid
Neovitamin A acid
Prestwick_642
Prestwick2_000256
Prestwick3_000256
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 43780
Ro 4-3780
Ro-43780
Ro-4-3780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
Sotret
Sotret (TN)
SPECTRUM1502013
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
|
|
16 |
|
Dopamine |
Approved |
Phase 3,Phase 1 |
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
hydroxytyramine
|
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
17 |
|
Cyproheptadine |
Approved |
Phase 3 |
|
129-03-3 |
2913
|
Synonyms:
129-03-3
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
41354-29-4
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
Biomol-NT_000131
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
CYPROHEPTADINE
Cyproheptadine (INN)
|
Cyproheptadine [INN:BAN]
Cyproheptadine Hcl
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
Lopac0_000246
Lopac-C-6022
LS-114933
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
nchembio.559-comp10
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
|
|
18 |
|
Histamine |
Approved, Investigational |
Phase 3 |
|
51-45-6, 75614-87-8 |
774
|
Synonyms:
.beta.-Imidazolyl-4-ethylamine
[3H]histamine
1avn
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1qft
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-[4-Imidazolyl]ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-Ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
51-45-6
53290_FLUKA
5-imidazoleethylamine
5-Imidazoleethylamine
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
beta-Aminoethylimidazole
beta-aminothethylglyoxaline
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
bmse000744
BSPBio_001117
BSPBio_002124
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
histamine
Histamine
|
Histamine (DCF)
Histamine [USAN]
Histamine Base
Histamine, Free Base
Histaminum
Histaminum (TN)
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L000292
L-Histamin base
L-histamine
L-Histamine
Lopac0_000595
Lopac-H-7250
LS-75835
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
nchembio.87-comp54
nchembio714-comp1
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
Spectrum_000845
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
ST073926
STK346752
STOCK5S-55669
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
|
|
19 |
|
Tretinoin |
Approved, Investigational, Nutraceutical |
Phase 3,Phase 2,Phase 1 |
|
302-79-4 |
5538
|
Synonyms:
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
[3H]Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
Aberel
Aberela
Aberela [Norway]
AC1L9GWO
AC1Q1J2J
AC-6824
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, Retinoic
Acid, trans-Retinoic
Acid, Vitamin A
Acide retinoique (french) (dsl)
Acide retinoique (French) (DSL)
Acnavit
Acnavit [Denmark]
AGN 100335
AGN 192013
Airol
Aknefug
Aknoten
AKOS000280845
Alitretinoin
All Trans Retinoic Acid
all trans-Retinoic acid
All Trans-Retinoic Acid
all-(e)-Retinoic acid
all-(E)-Retinoic acid
All-trans Retinoic Acid
all-trans-beta-Retinoic acid
all-trans-b-Retinoic acid
all-trans-Retinoic acid
Alltrans-retinoic acid
all-trans-Tretinoin
all-trans-Vitamin a acid
all-trans-Vitamin A acid
all-trans-Vitamin a1 acid
all-trans-Vitamin A1 acid
ALRT 1057
Amnesteem
ATRA
AT-RA
Atragen
Atra-IV
Atralin
Avita (TN)
Avita Gel
A-Vitaminsyre
A-Vitaminsyre [Denmark]
Avitoin
Avitoin [Norway]
BAL4079
beta all trans Retinoic Acid
beta-all-trans-Retinoic acid
beta-Ra
beta-Retinoic acid
beta-Retinoic Acid
Betarretin
BIDD:GT0483
BIDD:PXR0081
BML2-E05
bmse000562
BPBio1_000082
b-Retinoic acid
BRN 2057223
BSPBio_000074
BSPBio_001500
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
Claravis
Cordes vas
Cordes VAS [Germany]
CPD000058245
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
Effederm
Effederm [France]
EINECS 206-129-0
Epi-aberel
EU-0101061
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
|
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
Lopac0_001061
LS-1154
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
nchembio.154-comp2
Nexret
NSC 122758
NSC122758
NSC-122758
Panretin Gel
Panretyn
PDT-002-002
Potassium Salt, Tretinoin
Prestwick_424
Prestwick2_000257
Prestwick3_000257
R 2625
R0064
R2625_SIGMA
REA
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retinoate
Retinoic acid
RETINOIC acid
RETINOIC ACID, ALL TRANS
Retinoic acid, all-trans- (8CI)
Retinova
Retionic acid
Retionic Acid
Retisol-A
Ro 1-5488
S1653_Selleck
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
SAM002264647
SMR000058245
Sodium Salt, Tretinoin
Solage
Sotret
SPECTRUM1502016
Spectrum5_001746
Spectrum5_001933
SR-01000000239
SR-01000000239-14
ST057075
Stieva-a
Stieva-A
Stieva-a Forte
trans Retinoic Acid
trans-Retinoic acid
Tretin m
Tretin M
tretinoin
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin [USAN:INN:BAN]
Tretinoin 0.1% cream or placebo
tretinoin liposome
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Trétinoïne
tretinoine (French) (EINECS)
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
TRETINON
Tri-Luma
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
|
|
20 |
|
Pancreatic Polypeptide |
Investigational |
Phase 3,Phase 1 |
|
59763-91-6 |
|
21 |
|
Veliparib |
Investigational |
Phase 2, Phase 3,Phase 1 |
|
912444-00-9 |
11960529
|
Synonyms:
(2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium
2-((2R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
ABT 888
|
|
|
22 |
|
Dianhydrogalactitol |
Investigational |
Phase 3 |
|
23261-20-3 |
|
23 |
|
Alkylating Agents |
|
Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
24 |
|
Dermatologic Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
25 |
|
Dihematoporphyrin Ether |
|
Phase 3,Phase 1 |
|
|
|
26 |
|
Ether |
|
Phase 3 |
|
|
|
27 |
|
Photosensitizing Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
28 |
|
Angiogenesis Inhibitors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
29 |
|
Angiogenesis Modulating Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
30 |
|
Antirheumatic Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
31 |
|
Immunosuppressive Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
32 |
|
Central Nervous System Depressants |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
33 |
|
Antimitotic Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
34 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
35 |
|
Keratolytic Agents |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
36 |
|
O(6)-benzylguanine |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
37 |
|
Antibodies |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
38 |
|
Antibodies, Monoclonal |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
39 |
|
Endothelial Growth Factors |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
40 |
|
Immunoglobulins |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
41 |
|
Mitogens |
|
Phase 3,Phase 1,Phase 2 |
|
|
|
42 |
|
Anesthetics |
|
Phase 3,Phase 1 |
|
|
|
43 |
|
Anesthetics, General |
|
Phase 3 |
|
|
|
44 |
|
Anesthetics, Inhalation |
|
Phase 3 |
|
|
|
45 |
|
Hematoporphyrin Derivative |
|
Phase 3 |
|
|
|
46 |
|
Hematoporphyrins |
|
Phase 3 |
|
|
|
47 |
|
Adjuvants, Anesthesia |
|
Phase 3 |
|
|
|
48 |
|
Analgesics |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
49 |
|
Analgesics, Opioid |
|
Phase 3 |
|
|
|
50 |
|
Anesthetics, Intravenous |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 470)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas |
Unknown status |
NCT00003788
|
Phase 3 |
carmustine;lomustine;porfimer sodium;procarbazine hydrochloride |
2 |
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma |
Completed |
NCT00017147
|
Phase 3 |
carmustine;O6-Benzylguanine |
3 |
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma |
Completed |
NCT00304031
|
Phase 3 |
Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle |
4 |
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma |
Completed |
NCT00884741
|
Phase 3 |
Temozolomide |
5 |
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma |
Completed |
NCT01480479
|
Phase 3 |
Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH |
6 |
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme |
Completed |
NCT00820963
|
Phase 3 |
temozolomide |
7 |
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme |
Completed |
NCT00482677
|
Phase 3 |
temozolomide |
8 |
Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme |
Completed |
NCT00002545
|
Phase 3 |
carmustine |
9 |
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
Completed |
NCT00006353
|
Phase 3 |
temozolomide |
10 |
SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme |
Completed |
NCT00003293
|
Phase 3 |
leflunomide;procarbazine hydrochloride |
11 |
Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma |
Completed |
NCT00003916
|
Phase 3 |
|
12 |
High Light and Low Light Dose PDT in Glioma |
Completed |
NCT00118222
|
Phase 3 |
porfimer sodium |
13 |
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma |
Completed |
NCT00052455
|
Phase 3 |
lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate |
14 |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
Completed |
NCT00538850
|
Phase 3 |
Fentanyl sublingual spray;Placebo |
15 |
E-MOSAIC Electronic Tool to Monitor Symptoms |
Completed |
NCT00477919
|
Phase 3 |
|
16 |
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors |
Completed |
NCT00369785
|
Phase 3 |
donepezil hydrochloride;Placebo |
17 |
A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification |
Recruiting |
NCT02573324
|
Phase 3 |
Temozolomide;ABT-414;Placebo for ABT-414 |
18 |
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
Recruiting |
NCT02152982
|
Phase 2, Phase 3 |
Temozolomide;Veliparib |
19 |
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM |
Active, not recruiting |
NCT03149575
|
Phase 3 |
VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin |
20 |
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer |
Terminated |
NCT01132547
|
Phase 3 |
cyproheptadine hydrochloride |
21 |
Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors |
Terminated |
NCT00031798
|
Phase 3 |
methylphenidate hydrochloride |
22 |
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas |
Withdrawn |
NCT00003564
|
Phase 3 |
Isotretinoin;Procarbazine Hydrochloride |
23 |
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma |
Unknown status |
NCT01124539
|
Phase 2 |
AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) |
24 |
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
Unknown status |
NCT01013285
|
Phase 2 |
temozolomide |
25 |
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma |
Unknown status |
NCT00936052
|
Phase 2 |
|
26 |
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas |
Unknown status |
NCT01721577
|
Phase 1, Phase 2 |
AXL1717 |
27 |
Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
Unknown status |
NCT00486603
|
Phase 1, Phase 2 |
hydroxychloroquine;temozolomide |
28 |
Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
Unknown status |
NCT00006460
|
Phase 1, Phase 2 |
hyperbaric oxygen |
29 |
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma |
Unknown status |
NCT00114309
|
Phase 2 |
131-I-TM-601;131I-TM601 |
30 |
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas |
Unknown status |
NCT00492687
|
Phase 2 |
carboplatin;tamoxifen citrate;temozolomide |
31 |
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme |
Unknown status |
NCT00014105
|
Phase 1, Phase 2 |
carboplatin;temozolomide |
32 |
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme |
Unknown status |
NCT00054496
|
Phase 2 |
erlotinib hydrochloride |
33 |
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
Unknown status |
NCT00006656
|
Phase 2 |
carmustine in ethanol |
34 |
Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma |
Unknown status |
NCT00003176
|
Phase 2 |
carmustine;temozolomide |
35 |
A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain |
Unknown status |
NCT01403311
|
Phase 2 |
5-Aminolevuline Acid |
36 |
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm |
Unknown status |
NCT00009854
|
Phase 1, Phase 2 |
carmustine in ethanol |
37 |
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma |
Completed |
NCT00525525
|
Phase 2 |
Bevacizumab;Tarceva;Temozolomide |
38 |
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas |
Completed |
NCT00612339
|
Phase 2 |
Avastin and Temozolomide |
39 |
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
Completed |
NCT00335764
|
Phase 1, Phase 2 |
sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus |
40 |
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas |
Completed |
NCT00597402
|
Phase 2 |
Avastin;Temozolomide;Irinotecan |
41 |
Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients |
Completed |
NCT00402116
|
Phase 1, Phase 2 |
enzastaurin;temozolomide |
42 |
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors |
Completed |
NCT00187486
|
Phase 2 |
Tarceva;Temodar |
43 |
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma |
Completed |
NCT00433381
|
Phase 2 |
irinotecan hydrochloride;temozolomide |
44 |
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
Completed |
NCT00305864
|
Phase 1, Phase 2 |
Motexafin Gadolinium;Temozolomide |
45 |
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme |
Completed |
NCT00979017
|
Phase 2 |
Avastin;Temozolomide;Irinotecan |
46 |
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme |
Completed |
NCT00165477
|
Phase 2 |
lenalidomide |
47 |
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme |
Completed |
NCT00883298
|
Phase 2 |
temozolomide and bevacizumab |
48 |
AMG 102 and Avastin for Recurrent Malignant Glioma |
Completed |
NCT01113398
|
Phase 2 |
AMG 102;Avastin |
49 |
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma |
Completed |
NCT00028795
|
Phase 2 |
temozolomide |
50 |
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) |
Completed |
NCT01856933
|
Phase 2 |
PSMA ADC |
Cochrane evidence based reviews: gliosarcoma
|